Posted by Michael Wonder on 26 Jun 2016
Teva receives CHMP positive opinion for Cinqaero (reslizumab)
24 June 2016 - Add-on therapy targeting IL-5 in adults with severe eosinophilic asthma pending marketing authorization in Europe.
Teva Pharmaceutical Industries today announced that the EMA's CHMP has issued a positive opinion recommending marketing authorization for Cinqaero (reslizumab), a humanized interleukin 5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
View Teva Pharmaceuticals press release
